Pharma - Digital Health Partnerships in Oncology

Oncology treatments usually cause adverse effects that compromise patients quality of life (QoL), which may lead to treatment changes. Digital Health (DH) solutions have proven to help by minimizing symptoms, improving QoL, reducing hospitalizations and improving treatment adherence. Hence, it seems like a great opportunity for Pharma companies to bundle these solutions with their treatments as a way to improve patient outcomes and QoL and differentiate from others. Join us to discuss how to create valuable Pharma-DH partnerships in oncology:   

 -How can pharma leverage Digital Health to improve patients’ experience with their drugs? What is the ROI for pharma? 

 -When is the right moment to incorporate the Digital Health solution (during trials, promotion, or other)?  

 -Beyond financial reasons, what are the main drivers for pharma to incorporate digital health solutions in the care plans of their oncological drugs? 

- We have seen promising partnerships being formed in the last few years, such as, for instance, the collaboration between Voluntis and AstraZeneca as well as BMS, and Kaiku Health teaming up with Novartis and Roche. What are the results and key learnings of these partnerships so far?